UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000831
Receipt number R000000998
Scientific Title Trial in diabetic ulcer Using basic Fibroblast Growth Factor(KCB-1)
Date of disclosure of the study information 2007/09/21
Last modified on 2009/09/04 16:19:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Trial in diabetic ulcer Using basic Fibroblast Growth Factor(KCB-1)

Acronym

Trial in diabetic ulcer Using basic Fibroblast Growth Factor(KCB-1)

Scientific Title

Trial in diabetic ulcer Using basic Fibroblast Growth Factor(KCB-1)

Scientific Title:Acronym

Trial in diabetic ulcer Using basic Fibroblast Growth Factor(KCB-1)

Region

Japan


Condition

Condition

Diabetic ulcer

Classification by specialty

Endocrinology and Metabolism Dermatology Plastic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the clinical efficacy of KCB-1 for diabetic ulcer and the dose-response relationship.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Ulcer shrinkage evaluate: Grade 1 achievement {Marked reduction in the ulcer area (at least 75%) or depth (at least 75%) } during 8-week follow-up

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Dose comparison

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

KCB-1 0.01% administration group: 30micro gram of trafermin. once a day for 8 weeks.

Interventions/Control_2

KCB-1 0.001% administration group: 3 micro gram of trafermin. once a day for 8 weeks.

Interventions/Control_3

Placebo administration group: 0 micro gram of trafermin. once a day for 8 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) ulcer measuring 900 mm2 or less(Attending physicians selected a target ulcer in the presence of multiple ulcers.)
(2) age: =>20
(3) sex: male and female,
setting: hospitalized and outpatient
(4) patients providing written informed consent

Key exclusion criteria

(1) patients who have a target ulcer with a serious infection
(2) patients who have a target ulcer reaching the periosteum
(3) patients whose pulsation of the dorsal artery of foot or posterior tibial artery can not be palpable.
However, patients are enrolled in this study if the ankle-brachial index at rest is not less than 0.9 in patients with no palpable pulsation of either artery (excluding those with severe calcification due to maintenance hemodialysis or diabetes).
(4) patients with bedsores
(5) patients with a malignant tumor or a history of a malignant tumor
(6) patients with a history of hypersensitivity reactions to KCB-1
(7) patients with other serious comorbid disease
(8) patients receiving oral administration or injection of adrenocortical steroids at 20 mg/day or greater doses as prednisolone
(9) patients who participated in a clinical study within 6 months prior to this study
(10) women with confirmed or suspected pregnancy, nursing women, women who would like to become pregnant during the trial
(11) patients having been judged to be ineligible to participate in this study by the attending physicians for any other reason

Target sample size

150


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masutaka Furue

Organization

Kyushu University Hospital

Division name

Department of Dermatology

Zip code


Address

3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

KAKEN PHARMACEUTICAL CO., LTD.

Division name

Clinical Development Department

Zip code


Address

2-28-8, Honkomagome, Bunkyo-ku, Tokyo, 113-8650, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

KAKEN PHARMACEUTICAL CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

KAKEN PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 09 Month 21 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 10 Month 04 Day

Date of IRB


Anticipated trial start date

2004 Year 10 Month 01 Day

Last follow-up date

2006 Year 09 Month 01 Day

Date of closure to data entry

2006 Year 09 Month 01 Day

Date trial data considered complete

2006 Year 09 Month 01 Day

Date analysis concluded

2006 Year 11 Month 01 Day


Other

Other related information



Management information

Registered date

2007 Year 09 Month 21 Day

Last modified on

2009 Year 09 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000998


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name